Nürnberger W, Bönig H, Burdach S, Göbel U
Klinik für Pädiatrische Hämatologie und Onkologie, Heinrich-Heine-Universität, Düsseldorf, Germany.
Infection. 1998 Jan-Feb;26(1):65-7. doi: 10.1007/BF02768763.
The combination of piperacillin with tazobactam (PIP/TAZ) extends the activity of piperacillin against gram-positive, gram-negative, and anaerobic bacteria. The broad-spectrum of this formulation, together with its low degree of organ toxicity observed in adults, makes PIP/TAZ a tempting choice for children with radio-/chemotherapy-induced neutropenia. However, the use of PIP/TAZ is not yet approved for children under 12 years of age. The tolerability of PIP/TAZ was assessed in 19 children and adolescents between 2 and 18 years of age who developed a fever during aplasia after high dose radio-/chemotherapy and autologous stem cell transplantation (HD-SCT) for primary multifocal or relapsed solid tumours. Treatment with PIP/TAZ was initiated on average 3 days after HD-SCT, and the treatment was continued for approximately 10 days. Both clinical observation and laboratory studies showed no relevant alterations that would have been attributable to PIP/TAZ treatment. These results indicate that PIP/TAZ appears to be well tolerated in children during the acute phase of HD-SCT.
哌拉西林与他唑巴坦联合使用（PIP/TAZ）可扩大哌拉西林对革兰氏阳性菌、革兰氏阴性菌及厌氧菌的抗菌活性。该制剂的广谱抗菌特性，以及在成人中观察到的低器官毒性，使得PIP/TAZ成为患有放疗/化疗所致中性粒细胞减少症儿童的诱人选择。然而，PIP/TAZ在12岁以下儿童中的使用尚未获得批准。对19名年龄在2至18岁之间的儿童和青少年进行了PIP/TAZ耐受性评估，这些儿童和青少年因原发性多灶性或复发性实体瘤接受高剂量放疗/化疗及自体干细胞移植（HD-SCT）后在造血再生障碍期出现发热。PIP/TAZ治疗平均在HD-SCT后3天开始，持续约10天。临床观察和实验室研究均未显示出与PIP/TAZ治疗相关的显著改变。这些结果表明，在HD-SCT急性期，儿童对PIP/TAZ的耐受性似乎良好。
